Cimzia, a biologic anti-TNF therapy, has been approved by the U.S. FDA for Crohn’s disease. This is good news for psoriasis patients as well, because Cimzia was shown two years ago to be effective in a Phase Two psoriasis trial. Our philosophy regarding treatment options is pretty straightforward: the more options for psoriasis patients, the better.
While the FDA approval for Crohn’s means Cimzia can now be prescribed off-label as a psoriasis treatment, most insurers will want to see further clinical testing and FDA approval before reimbursing Cimzia as a psoriasis treatment, particularly since five biologics are already FDA-approved for psoriasis.
Cimzia is a product of European pharmaceutical giant UCB.
[More info: other experimental psoriasis treatments.]
Category: Uncategorized
